Fig. 6
Pre-treatment with selumetinib enhances the activity of anti-CTLA-4 in the CT26 tumor model. a Schema showing treatment schedules for vehicle control, selumetinib, anti-CTLA-4 mAb and concurrent combination. Anti-CTLA-4 antibodies were administered on day 7 and then twice per week for a total of 4–6 doses at 10 mg/kg. Selumetinib was administered orally on day 7 at 25 mg/kg twice daily for 18–28 days (b) Sequential treatment with selumetinib administered on day 4 for 5 days followed by 1 day of no treatment; anti-CTLA-4 antibody was administered on day 10 and then twice a week for a further 5 doses at 10 mg/kg. Kaplan-Meier survival curves for mice bearing CT26 mouse colorectal tumors are shown. *P < 0.05 as determined by Log-Rank Mantel-Cox test between indicated groups. c Tumor volumes (mm3) at indicated days post-cell implantation with or without short-term selumetinib pre-treatment (dosing regimen represented in B). Unpaired t-tests performed. * P < 0.05. Plotted are mean ± SEM. Data shown are representative of 2 independent experiments